Extended Data Fig. 2: Provisional PPARG protein cutoff informed by real-world molecular characterization and on-study biomarker data.
From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
A & B, In the Tempus xT real-world cohort (N = 2,685 patients), PPARG is enriched in luminal tumors and a range of PPARG mRNA thresholds identifies luminal lineage with high sensitivity and PPV (Youden’s J stable from 6.1–7.1 log2[TPM + 1]). C, Linear regression line (red solid line) with pointwise 99% confidence band (shaded region) of baseline tumor PPARG mRNA versus protein expression (N = 26 patients; on-study biomarker data) maps a provisional TPS cutoff of ≥60% to an mRNA range of 6.1–7.1, corresponding to >74.5% sensitivity and >81% PPV. Two-sided p value from Pearson’s correlation test is shown. D, PPARG protein expression is significantly higher in luminal (N = 23) versus non-luminal (N = 6) tumors (on-study biomarker data; see Suppl. Table 10). Boxplots display the median and interquartile range; whiskers denote the 5th–95th percentile range; the + symbol denotes the mean (A, D). Two-sided Wilcoxon rank-sum test was used for statistical analysis in (A, D).
